CRDOMEDIUM SIGNALFINANCIAL10-K

CRDO transitioned to a 53-week fiscal year while substantially expanding R&D and SG&A investments, accompanied by meaningfully higher operating cash flow generation.

The company appears to be in a significant investment phase, with R&D and SG&A expenses both growing substantially year-over-year, suggesting either aggressive growth initiatives or potential integration costs. However, the strong improvement in operating cash flow indicates the business fundamentals remain solid despite the increased spending levels.

Comparing 2025-07-02 vs 2024-06-24View on EDGAR →
FINANCIAL ANALYSIS

CRDO showed a mixed financial picture with substantially higher operating expenses across both R&D and SG&A functions, reflecting significant investment in growth or operations. However, operating cash flow generation improved meaningfully, suggesting strong underlying business performance that more than offset the increased spending. The balance sheet strengthened notably with current assets and total assets both expanding over 34%, while stockholders' equity grew by over 26%, indicating solid financial positioning despite the elevated investment levels.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
+98.8%
$32.7M$65.1M

Operating cash flow surged 98.8% — exceptional cash generation, highest quality earnings signal.

SG&A Expense
P&L
+64.3%
$60.2M$98.9M

SG&A up 64.3% — significant increase in sales or administrative costs, monitor impact on operating leverage.

R&D Expense
P&L
+52.8%
$95.5M$146.0M

R&D investment increased 52.8% — signals commitment to future product development, though near-term margin impact.

Current Assets
Balance Sheet
+34.6%
$530.3M$713.5M

Current assets grew 34.6% — improving short-term liquidity or inventory/receivables build.

Total Assets
Balance Sheet
+34.4%
$601.9M$809.3M

Asset base grew 34.4% — expansion through organic growth, acquisitions, or capital deployment.

Stockholders Equity
Balance Sheet
+26.2%
$540.2M$681.6M

Equity base grew 26.2% — retained earnings accumulation or equity issuance strengthening the balance sheet.

LANGUAGE CHANGES
NEW — 2025-07-02
PRIOR — 2024-06-24
ADDED
The registrant had 171,641,835 ordinary shares outstanding as of June 13, 2025.
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 104 Item 9A.
The Company s fiscal year is a 52- or 53-week period ending on the Saturday closest to April 30.
The additional week in a 53-week year is added to the first quarter, making such quarter consist of 14 weeks.
Accordingly, every fifth or sixth fiscal year will have a 53-week period.
+7 more — sign up free →
REMOVED
The registrant had 165,185,407 ordinary shares outstanding as of June 17, 2024.
Changes in and Disagreements w ith Accountants on Accounting and Financial Disclosure 105 Item 9A.
Effective May 1, 2022, the Company changed its fiscal year to a 52- or 53-week period ending on the Saturday closest to April 30.
Our fiscal year ending April 27, 2024 (fiscal 2024) is a 52-week fiscal year.
The first quarter of fiscal 2024 ended on July 29, 2023, the second quarter ended on October 28, 2023 and the third quarter ended on January 27, 2024.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →